Part of the reason I decided to spend some time writing and talking about EBV this year, is that the last 5 years in the medical literature has had a strong and interesting lens focussed on EBV and autoimmune disease.
And in 2024 and 2025 there was some significant assessment of the mechanism by which EBV is involved in the direct initiation of autoimmune disease.
So maybe you are already working with autoimmunity (it affects 10% of the population now) or maybe you have an interest in EBV already and because of that are attracting autoimmune cases.
Or, many of us work with Long Covid cases and EBV reactivation as part of Long Covid is important too.
EBV is known to be involved in multiple autoimmune diseases. Hashimoto’s. Lupus. Multiple sclerosis. Sjögren’s. Rheumatoid arthritis.
And increasingly, post-viral and post-COVID autoimmune patterns.
What role does EBV actually play in autoimmunity?
Is it a cause?
A trigger?
A perpetuator?
Or simply an innocent bystander?
The answer, as with most things in immunology, is context-dependent.
The Shift in the EBV–Autoimmunity Conversation
Over the past decade, the conversation around EBV and autoimmune disease has evolved significantly.
In conditions such as multiple sclerosis and systemic lupus erythematosus, EBV is now widely discussed as necessary for the development of these diseases.
As you can imagine, this has caused QUITE a stir. Not the least because >90% of the global population is infected with this virus.
But if most of us have it, but only 10% of us have autoimmunity, then what’s missing?
What I’m not seeing talked about is that EBV might be necessary, but it’s not sufficient!
EBV exposure appears to be required in many cases, but cannot explain disease development on its own.
If EBV were sufficient on its own, autoimmune disease would be nearly universal. Instead, what we see is selective vulnerability — where EBV intersects with genetic susceptibility, immune dysregulation, and environmental load to produce disease in some individuals but not others.
Basically, it’s part of the immunological lasagne. A single layer of pasta is NOT a lasagne. And a single immune variable is not sufficient for autoimmunity.
A lasagne requires multiple layers in a specific sequence until the dish is completed.
Each ‘layer’ of autoimmunity is affected by what came before it, and affects what comes after it.
Another way of saying this is that immune terrain affects the outcome of any individual event.
This moves EBV out of the role of sole villain and into a more nuanced position:
a potential trigger or amplifier within a dysregulated immune system.
How EBV Interacts With the Immune System in Autoimmunity
EBV is uniquely positioned to influence autoimmune processes because of the cells it infects and the immune pathways it engages.
EBV primarily infects B lymphocytes — cells central to:
- Antibody production
- Antigen presentation
- Immune memory
In autoimmune disease, B cells are often already dysregulated. When EBV persists within these cells, several mechanisms may contribute to immune dysfunction, including:
- Altered B-cell activation and survival
- Disrupted immune tolerance
- Molecular mimicry between viral and self-tissues
- Chronic immune activation and inflammatory signalling
Importantly, these processes do not occur in isolation. They unfold over time, shaped by immune resilience, regulatory capacity, and cumulative physiological stress.
EBV can create immune dysregulation that is a base layer of the ‘lasagne’ that means everything layered over the top moves the body closer to autoimmunity with each step, especially if EBV has initiated cross reactive reactions to tissue or citrullination of tissues.
In addition, EBV can exploit or amplify existing immune dysregulation. Throwing a molotov cocktail onto a pre-existing smouldering-but-managed environment in the body.
Tissue Specificity: Why Autoimmunity Looks Different Across Conditions
One of the more compelling aspects of EBV-associated autoimmunity is tissue specificity.
In different autoimmune conditions, EBV-infected immune cells appear to localise or exert influence in different tissues:
- Thyroid tissue in autoimmune thyroid disease
- Central nervous system in multiple sclerosis
- Salivary glands in Sjögren’s syndrome
- Gut-associated lymphoid tissue in inflammatory bowel disease
This supports the idea that EBV participates in autoimmunity through interaction with existing immune vulnerabilities, rather than acting as a universal trigger.
From a clinical perspective, this explains why:
- EBV appears relevant in some autoimmune cases but not others
- Viral markers don’t correlate neatly with symptom severity
- Treating EBV alone rarely reverses established autoimmunity
Also please remember that “Autoimmunity is Never Always Anything” – so even in well defined EBV associated autoimmune diseases like MS, EBV is NOT necessarily a problem. We really cannot assume.
Why “Treating EBV” Is Not the Same as Treating Autoimmunity
One of the most common clinical pitfalls is the magic bullet thinking that concludes that addressing EBV will automatically improve autoimmune disease.
While it might be an important step, there’s a couple of critical caveats here:
- If a hammer breaks a window and you take away the hammer, the window is still broken.
In reality, autoimmunity reflects loss of immune tolerance, not simply the presence of a pathogen.
By the time autoimmune disease is established, the immune system is no longer just responding to an external challenge — it is reacting to self. This involves:
- Dysregulated T-cell responses
- Impaired regulatory pathways
- Chronic inflammatory signalling
- Altered tissue–immune communication
In this context, EBV may continue to act as an immune stressor, but removing or suppressing it does not restore tolerance. (The window is still broken)
Many practitioners observe partial or temporary improvement when focusing narrowly on EBV because the antigen burden has decreased significantly for a while— followed by relapse or plateau.
You need to address the broken window.
And because the immune system defaults to STABILITY not necessarily healthy homeostasis – Autoimmune disease requires a different clinical lens.
Sequencing Matters
When the immune system is already operating at the edge of capacity. Aggressive attempts to “treat” infections, detoxify aggressively, or push immune modulation without stabilisation can worsen symptoms rather than improve them.
A more effective approach prioritises:
- Stabilisation — reducing inflammatory load and physiological stress
- Regulation — supporting immune tolerance and resilience
- Contextual intervention — addressing drivers at the right time, in the right order
Within this framework, EBV becomes one piece of a comprehensive immune picture — not the starting point, and not the sole focus.
(no magic-bullet thinking please)
A Clinical Reframe
EBV does not explain autoimmunity on its own — but it can offer insight into immune vulnerability, regulatory failure, and disease persistence.
Why This Requires a Systems-Based Approach
Autoimmune disease does not respond well to siloed thinking.
Understanding the role of EBV in autoimmunity requires:
- Immunology, not just infection models
- Pattern recognition across systems
- Comfort with uncertainty and complexity
- A framework for sequencing rather than targeting
This is where many practitioners feel stretched — not because they lack intelligence or commitment, but because autoimmune cases demand a different level of clinical reasoning.
Ready to Go Deeper?
If EBV and autoimmunity are showing up in your practice, the next step isn’t learning another protocol.
It’s learning how to think in systems, sequence care appropriately, and restore immune tolerance over time.
👉 The Autoimmune Academy is designed to support practitioners in exactly this work — integrating immunology, clinical reasoning, and real-world case management.
This is where EBV becomes one part of a coherent autoimmune framework — rather than an isolated problem to solve.
(For a resource to help you with practical knowledge you can implement right away, check out my free EBV Practitioners Guide)
